stars 1 stars 2 stars 3

BioGenix grew out of the recognition of the important potential of regenerative medicine in giving hope to patients who suffer from past injuries, chronic conditions, or degenerative disease. Out of this potential grew the demand for safe, reliable, ethically sound regenerative products -- and BioGenix was up to the task. Working directly with hospitals participating in umbilical cord tissue donation programs and partnering with a trusted, sterile FDA registered lab, we turned concept into reality, bringing BioGenix regenerative products to physicians across many medical specialties domestically and around the world. By choosing to use only umbilical cord derived regenerative medicine products, we harness the medical advantages of growth-factor rich tissue while circumventing invasive procedures and providing a product that aligns with our ethics.

BioGenix Questions

The BioGenix annual revenue was $7.8 million in 2026.

Michael Stavitski is the President South East Asia of BioGenix.

14 people are employed at BioGenix.

Top BioGenix Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users